Sargent Investment Group LLC Purchases New Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Sargent Investment Group LLC acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the second quarter, HoldingsChannel reports. The institutional investor acquired 601 shares of the medical equipment provider’s stock, valued at approximately $267,000.

Several other hedge funds have also modified their holdings of the company. One Wealth Management Investment & Advisory Services LLC increased its position in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after purchasing an additional 23 shares during the last quarter. Indiana Trust & Investment Management CO increased its holdings in shares of Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock worth $222,000 after buying an additional 25 shares during the last quarter. Hoxton Planning & Management LLC raised its position in shares of Intuitive Surgical by 4.9% during the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares in the last quarter. First Affirmative Financial Network lifted its holdings in shares of Intuitive Surgical by 2.7% in the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after acquiring an additional 26 shares during the last quarter. Finally, Moors & Cabot Inc. grew its position in Intuitive Surgical by 2.3% in the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock worth $516,000 after acquiring an additional 26 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ISRG has been the topic of a number of recent research reports. Truist Financial upped their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. BTIG Research raised their price target on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Robert W. Baird boosted their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. JPMorgan Chase & Co. raised their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Finally, Citigroup lifted their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $446.45.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,458,979.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,120 shares of company stock worth $25,528,753. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Trading Down 1.6 %

Shares of ISRG stock opened at $483.32 on Wednesday. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $496.18. The stock has a fifty day simple moving average of $465.50 and a two-hundred day simple moving average of $423.39. The stock has a market capitalization of $171.43 billion, a price-to-earnings ratio of 87.24, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 earnings per share. Research analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.